Radiotherapy and Oncology (RADIOTHER ONCOL )

Publisher: European Society for Therapeutic Radiology and Oncology, Elsevier

Description

Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as physical aspects relevant to oncology, particularly in the field of imaging, dosimetry and radiation therapy planning. Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published. Papers are accepted on a worldwide basis.

  • Impact factor
    4.52
    Show impact factor history
     
    Impact factor
  • 5-year impact
    4.42
  • Cited half-life
    5.60
  • Immediacy index
    0.93
  • Eigenfactor
    0.03
  • Article influence
    1.21
  • Website
    Radiotherapy & Oncology website
  • Other titles
    Radiotherapy and oncology (Online), Radiotherapy & oncology
  • ISSN
    0167-8140
  • OCLC
    39118982
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Elsevier

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Voluntary deposit by author of pre-print allowed on Institutions open scholarly website and pre-print servers
    • Voluntary deposit by author of authors post-print allowed on institutions open scholarly website including Institutional Repository
    • Deposit due to Funding Body, Institutional and Governmental mandate only allowed where separate agreement between repository and publisher exists
    • Set statement to accompany deposit
    • Published source must be acknowledged
    • Must link to journal home page or articles' DOI
    • Publisher's version/PDF cannot be used
    • Articles in some journals can be made Open Access on payment of additional charge
    • NIH Authors articles will be submitted to PMC after 12 months
    • Authors who are required to deposit in subject repositories may also use Sponsorship Option
    • Pre-print can not be deposited for The Lancet
  • Classification
    ​ green

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and purpose Scanned-beam interplay with the intrafraction target motion may result in dose deterioration in particle therapy. The magnitude of this effect and the possibilities to mitigate it were investigated for carbon ion prostate treatments. Methods and materials For 12 prostate cases, 9 carbon ion treatment plans were prepared using 3 scanned-beam settings (spot sizes of 6, 7 and 9 mm and, respectively, raster pitches of 2, 2 and 3 mm) for 3 planning margins (3, 6 and 9 mm). Plans were recomputed in presence of 5 intrafraction prostate motion scenarios with and without intra-beam motion compensation. Results For 6 mm margin and 7 mm spot, the median (max) CTV D95% change was −0.2 (−2.6) pp (percentual points) with pure drift motion, −3.8 (−6.0) pp and −2.8 (−3.1) pp in transient motion scenarios and −4.8 (−7.7) pp and −1.8 (−5.7) pp in mixed motion scenarios. No particular raster setting brought distinct advantage, while planning margin expansion showed statistically significant effects for drift-dominated scenarios. Intra-beam motion compensation yielded improved CTV coverage. Conclusion Intrafraction prostate motion can lead to marked target coverage deterioration, dependent on individual motion patterns, which can be only partially avoided through planning-time countermeasures. Among possible delivery-time countermeasures, intra-beam motion compensation is capable of improving target coverage.
    Radiotherapy and Oncology 05/2014;
  • Radiotherapy and Oncology 01/2014; 111:705-706.
  • Radiotherapy and Oncology 08/2013; S0167-8140(13)00326-5..
  • Radiotherapy and Oncology 03/2013; 106(1):s109.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose/Objective: The demand for safety and quality assurance in RT is becoming increasingly urgent. This is a need felt by professionals involved, caused by the growing complexity of RT techniques and technologies involved in treatment delivery, as well as by patients, because of the increasing attention paid by non- specialist press to RT accidents. As an associate member of a National Project financed by the National Institute of Nuclear Physics, aiming to development of in vivo dosimetry (IVD) procedures for RT, our Institution have participated in testing the IVD procedure and software, specific for 3DCRT. Here we propose the preliminary results of a trial aiming to IVD integration in quality management of pelvic RT. Materials and Methods: 15 consecutive patients undergone to 3DCRT for pelvic cancer (prostate, rectum or gynecologic tumors) were selected. A personalized 3DCRT treatment plan was prepared for all of them, consisting of a set of 4 or 5 MLC conformed beams (open or wedged beams), with an isocentric prescription dose/fraction of 1.8 Gy, (number of fractions ranging between 25 and 43). DRRs of a couple of square orthogonal isocentric fields were also obtained for patient setup verification on linac couch. Geometric and dosimetric plan data were then transferred to the R&V Network, to make them allowable to both linac interface and IVD software. An integrated approach, based on scheduled setup verifications (SVs) and IVD checks has been tested for each selected patient during the course of RT, consisting of: i) a comparison between the EPID images of the couple of orthogonal beams and the corresponding DRRs before treatment delivery and ii) the calculation for each field of R ratio between the TPS calculated isocentric dose and the delivered dose during the treatment session. Results: As SVs and IVD checks were scheduled on different treatment days, total amount of time required for tests during a treatment session resulted compatible with staff workload. For all tested patients SVs showed average deviations equal to 2.9 mm, with every single value below the action level (±4 mm), confirming a day by day setup reproducibility inside quality standard. A total of 176 IVD tests were performed on 44 different sessions. In 84% of the IVD checks the results were within the accepted tolerance of 5% for R. In the 16% of cases, 1 or more R values resulted out of tolerance. The average R value on each of the 44 sessions resulted within tolerance range in 93% of cases. A more detailed analysis of unsuccessful tests revealed the following causes for dose discrepancy: presence of gas pockets, attenuating media on beam axis at beam exit, random loss of patient setup during treatment. Conclusions: An integrated approach based on SVs and an IVD tests can be a valuable tool in quality management of pelvic 3DCRT: in case of discrepancy between delivered and planned doses, IVD gives to RT team the chance to analyze and program adequate corrections in further RT sessions.
    Radiotherapy and Oncology 03/2013; 106((S2)):S439.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose/Objective: To investigate the association between initial body mass index (BMI) and hemoglobin level and chemoradiation therapy (CRT) outcomes in head and neck cancer patients. Materials and Methods: 126 patients with head and neck squamous cell carcinoma were treated with primary cisplatin-based chemoradiotherapy at our Institution. For all patients initial BMI, pretreatment hemoglobin level and Hb nadir were evaluated. Other parameters with potential prognostic relevance were assessed and correlated with clinical outcome as tumor localization, T stage, N stage, age, performance status, smoking habits, duration of treatment course. Statistical analysis was performed to asses relationship between each of the clinicopathologic variables and overall survival (OS), disease-specific survival (DSS), local relapse-free survival (LRFS) and metastatic disease-free survival (MDFS). Results: Tumor arose from oropharynx in 69 patients, oral cavity in 23 patients, hypopharynx in 21 patients and larynx in 13 patients. All patients were restaged according to the 2002 criteria of the International Union Against Cancer and included 26 with stage III and 100 with stage IVA and B. Eighty-three patients showed clinical nodal involvement, while 28 patients had no evidence of disease at this site. Out of the 126 patients, 95 were males and 31 were females; 96 patients were current or former smoker. The mean age at diagnosis was 59 years (range 37-78 years; median age: 60 years). All patients received external beam irradiation on the primary site of disease and bilateral regional lymph node areas. In most cases (77%) a dose greater than 66 Gy was delivered. All patients underwent cisplatin-based concurrent chemotherapy. Patients with normal or low BMI (BMI < or =25 kg/m) had significantly shorter OS both at univariate analysis (p=0.005) with a protective effect of BMI >25 at multivariate analysis (HR 0.56; 95% CI (0.32-0.96), P=0.037). Patients with hemoglobin nadir level ≤ 10 g/dL had significantly worse DSS at univariate analysis (p=0.0001): this result was confirmed at multivariate analysis (HR 2.77; 95% CI (1.53-5.02) , P =0.0007). Patients with HB_nadir <10 have higher rate of persistence of disease (60% vs. 33%, p=0.041). BMI and Hb nadir were not independent determinants of impaired LRFS and MDFS at multivariate analysis. Conclusions: The present study suggests that BMI ≤ 25 and Hb nadir level < 10g/dl are predictors of poor outcome in patients eligibles for CRT. These results confirms the need for early nutritional support in head and neck cancer patients receiving intensive treatments like CRT, and the urge for further investigation on the relationship between low hemoglobin value and hypoxia-induced radioresistance.
    Radiotherapy and Oncology 02/2013; 106(S1):S47.
  • Radiotherapy and Oncology 01/2013; accepted.
  • Radiotherapy and Oncology 01/2013; 106(Supplementary 2):277-278.
  • Radiotherapy and Oncology 01/2013; 106(Supplement 1):S53.

Related Journals